HIGHLIGHTS
- who: Dongcheng Luo from the visited Guangxi Medical University Afufb01liated Tumor Hospital onUnited States have published the research: Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1), in the Journal: (JOURNAL) of 27/01/2022
- how: The results showed that the mPFS was 5.0 months and mOS was 9.0 months in the anlotinib combination group which were significantly improved compared with those of AG regimen (mPFS=2.7 months mOS=6.0 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.